You are here

Article Text

Article menu

Download PDFPDF

Abstracts of Oral Presentations
OA-484 Improving rapid detection of 2nd line drug resistance in Mycobacterium tuberculosis with Xpert MTB/XDR and MolBio 2nd line
Free
  1. Faridath Massou1,
  2. Awa Ba2,
  3. Kindy Sadio Bah3,
  4. Comfort Vuchas4,
  5. Fadeyi Muse5,
  6. Michel Kayomo Kaswa6,
  7. Claude Semuto7,
  8. Gemeda Abebe8,
  9. Bassirou Diarra9,
  10. Bouke de Jong10,
  11. Philip Supply11,
  12. Sian Flyod12,
  13. Corinne Merle13,
  14. Dissou Affolabi1
  1. 1Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou, Benin
  2. 2Université Cheick Anta Diop, Senegal
  3. 3Service de Pneumophtisiologie, Guinée
  4. 4The Bamenda Center for Health Promotion and Research, Cameroon
  5. 5Damien Foundation, Nigeria
  6. 6Institut National pour la Recherche Biomédicale, Democratic Republic of Congo
  7. 7Rwanda Biomedical Center, Rwanda
  8. 8Jimma University, Ethiopia
  9. 9University of Sciences Techniques and Technologies of Bamako, Mali
  10. 10Institute of Tropical Medicine, Belgium
  11. 11Genoscreen, France
  12. 12London School of Hygiene and Tropical Medicine, UK
  13. 13World Health Organization, Switzerland

Abstract

Background Rapid detection of resistance to key drugs such as fluoroquinolones (FQ) and bedaquiline (BDQ) is essential for appropriate management of multi-drug resistant tuberculosis (MDR-TB). . Molecular tests available require either infrastructures not available in peripheral laboratories in low resource countries, or do not detect resistance to BDQ. Recently, two tests have been developed: GeneXpert MTB/XDR (Cepheid, USA) detecting resistance to isoniazid (INH), FQ and ethionamide (ETH), and TrueNat XDR (Molbio Diagnostics, India) for detection of resistance to INH, FQ and BDQ.

Methods In the EDCTP-funded project (DIAMA) aimed at developing culture free approaches for diagnosis and management of MDR-TB patients, we assessed the performances of these tests in field conditions compared to phenotypic drug-susceptibility testing (pDST) and whole genome sequencing (WGS) using 1711 unique samples consecutively collected in the Sub-Saharan African region (Benin, Cameroon, DRC, Ethiopia, Guinea, Mali, Nigeria, Rwanda and Senegal).

Results Using a composite reference standard comprising pDST and WGS, Xpert-XDR showed a sensitivity of 87.3% for INH, 37.8% for ETH and 66.7% for FQ, with a respective specificity of 96.5%, 98.3% and 99.7%. For TrueNat, the sensitivity was 88.1% for INH and 47.4% for FQ, with a specificity of 85.7% for INH, 97.7% for FQ and 98.5% for BDQ.

Conclusion These tests showed promising results, particularly as screening test for detection of resistance to FQ and BDQ.

https://doi.org/10.1136/bmjgh-2023-EDC.36

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.